Cargando…

Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer

The outcome of radiofrequency ablation (RFA) for liver metastases from colorectal cancer (CRLM) has been thought to be inferior to metastasectomy. However, the recent development of multielectrode RFA (multi-RFA) systems has made the ablation zone larger and more complete. Thus, we assessed the surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Hou-Ying, Huang, Kai-Wen, Liang, Jin-Tung, Lin, Been-Ren, Huang, John, Hung, Ji-Shiang, Chen, Chi-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396979/
https://www.ncbi.nlm.nih.gov/pubmed/34442007
http://dx.doi.org/10.3390/jcm10163712
_version_ 1783744499842809856
author Cheng, Hou-Ying
Huang, Kai-Wen
Liang, Jin-Tung
Lin, Been-Ren
Huang, John
Hung, Ji-Shiang
Chen, Chi-Ling
author_facet Cheng, Hou-Ying
Huang, Kai-Wen
Liang, Jin-Tung
Lin, Been-Ren
Huang, John
Hung, Ji-Shiang
Chen, Chi-Ling
author_sort Cheng, Hou-Ying
collection PubMed
description The outcome of radiofrequency ablation (RFA) for liver metastases from colorectal cancer (CRLM) has been thought to be inferior to metastasectomy. However, the recent development of multielectrode RFA (multi-RFA) systems has made the ablation zone larger and more complete. Thus, we assessed the survival benefits of this modality in cases of metachronous CRLM. This retrospective study assessed patients diagnosed with resectable metachronous CRLM between 2013 and 2016; 132 patients were categorized by treatment for liver metastases: multi-RFA (n = 68), hepatectomy (n = 34), or systemic treatment only (n = 30). Therapeutic effectiveness, outcomes, and intervention-related complications were compared between groups. Median overall survival (OS), recurrence-free survival (RFS), and intrahepatic recurrence-free survival (IHRFS) were 69.8, 85.2, and 59.7 months for the hepatectomy group; 53.4, 41.3, and 32.3 months for the multi-RFA group; and 19.1, 7.1, and 7.1 months for the systemic treatment group. No significant differences were observed between the multi-RFA and hepatectomy groups after a median follow-up of 59.8 months. This study demonstrated that multi-RFA and hepatectomy provide similar survival benefits for patients with resectable CRLM. Multi-RFA may represent a reliable treatment option for the management of resectable liver metastases.
format Online
Article
Text
id pubmed-8396979
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83969792021-08-28 Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer Cheng, Hou-Ying Huang, Kai-Wen Liang, Jin-Tung Lin, Been-Ren Huang, John Hung, Ji-Shiang Chen, Chi-Ling J Clin Med Article The outcome of radiofrequency ablation (RFA) for liver metastases from colorectal cancer (CRLM) has been thought to be inferior to metastasectomy. However, the recent development of multielectrode RFA (multi-RFA) systems has made the ablation zone larger and more complete. Thus, we assessed the survival benefits of this modality in cases of metachronous CRLM. This retrospective study assessed patients diagnosed with resectable metachronous CRLM between 2013 and 2016; 132 patients were categorized by treatment for liver metastases: multi-RFA (n = 68), hepatectomy (n = 34), or systemic treatment only (n = 30). Therapeutic effectiveness, outcomes, and intervention-related complications were compared between groups. Median overall survival (OS), recurrence-free survival (RFS), and intrahepatic recurrence-free survival (IHRFS) were 69.8, 85.2, and 59.7 months for the hepatectomy group; 53.4, 41.3, and 32.3 months for the multi-RFA group; and 19.1, 7.1, and 7.1 months for the systemic treatment group. No significant differences were observed between the multi-RFA and hepatectomy groups after a median follow-up of 59.8 months. This study demonstrated that multi-RFA and hepatectomy provide similar survival benefits for patients with resectable CRLM. Multi-RFA may represent a reliable treatment option for the management of resectable liver metastases. MDPI 2021-08-20 /pmc/articles/PMC8396979/ /pubmed/34442007 http://dx.doi.org/10.3390/jcm10163712 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cheng, Hou-Ying
Huang, Kai-Wen
Liang, Jin-Tung
Lin, Been-Ren
Huang, John
Hung, Ji-Shiang
Chen, Chi-Ling
Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer
title Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer
title_full Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer
title_fullStr Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer
title_full_unstemmed Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer
title_short Multielectrode Radiofrequency Ablation for Resectable Metachronous Liver Metastasis from Colorectal Cancer
title_sort multielectrode radiofrequency ablation for resectable metachronous liver metastasis from colorectal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396979/
https://www.ncbi.nlm.nih.gov/pubmed/34442007
http://dx.doi.org/10.3390/jcm10163712
work_keys_str_mv AT chenghouying multielectroderadiofrequencyablationforresectablemetachronouslivermetastasisfromcolorectalcancer
AT huangkaiwen multielectroderadiofrequencyablationforresectablemetachronouslivermetastasisfromcolorectalcancer
AT liangjintung multielectroderadiofrequencyablationforresectablemetachronouslivermetastasisfromcolorectalcancer
AT linbeenren multielectroderadiofrequencyablationforresectablemetachronouslivermetastasisfromcolorectalcancer
AT huangjohn multielectroderadiofrequencyablationforresectablemetachronouslivermetastasisfromcolorectalcancer
AT hungjishiang multielectroderadiofrequencyablationforresectablemetachronouslivermetastasisfromcolorectalcancer
AT chenchiling multielectroderadiofrequencyablationforresectablemetachronouslivermetastasisfromcolorectalcancer